Hua Dong

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

Claire Harrison, Alessandro M. Vannucchi, Uwe Platzbecker et al. · The Lancet Haematology · 2017 · 315 citations

Medicine, Hematology, Pharmacology +5

Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States

Caron A. Jacobson, Frederick L. Locke, Long Ma et al. · Transplantation and Cellular Therapy · 2022 · 181 citations · Full text

Medicine, Hematology, Oncology +13

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma

Al B. Benson, Zev A. Wainberg, J. Randolph Hecht et al. · The Oncologist · 2017 · 176 citations · Full text

Medicine, Oncology, Pharmacology +14

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis

Melvin Churchill, Luis Felipe Flores-Suárez, Mario H. Cardiel et al. · Arthritis Research & Therapy · 2013 · 105 citations · Full text

Medicine, Immunology, Pharmacology +17

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Marcelo C. Pasquini, Frederick L. Locke, Alex F. Herrera et al. · Blood · 2019 · 95 citations

Medicine, Hematology, Oncology +15